NEW YORK (GenomeWeb) – In competing notes to investors today, analysts at Evercore ISI and Piper Jaffray have issued new opinions on Hologic, with Evercore downgrading the company to Hold from Buy, and Piper Jaffray upgrading it to Overweight from Neutral.

The banks also changed their price targets for Hologic. Evercore lowered its target to $42 while Piper Jaffray raised its to $48.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.